FDA accepts Eisai’s BLA for LEQEMBI subcutaneous autoinjector for alzheimer’s disease treatment
LEQEMBI’s subcutaneous formulation could simplify maintenance therapy for Alzheimer’s patients, offering a 15-second at-home…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.